Technical Analysis for SNG - Synairgen Plc

Grade Last Price % Change Price Change
A 200.05 -2.22% -4.55
SNG closed up 0.29 percent on Wednesday, December 1, 2021, on 81 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical SNG trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish -2.82%
Pocket Pivot Bullish Swing Setup -2.82%
Doji - Bearish? Reversal -2.82%
Stochastic Reached Overbought Strength -2.82%
Upper Bollinger Band Walk Strength -2.82%
Multiple of Ten Bullish Other -2.82%
Above Upper BB Strength -2.82%
Overbought Stochastic Strength -2.82%
Up 3 Days in a Row Strength -2.82%
Up 4 Days in a Row Strength -2.82%
Older End-of-Day Signals for SNG ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low 40 minutes ago
Down 3% 40 minutes ago
Fell Below Upper Bollinger Band about 1 hour ago
Down 2% about 1 hour ago
Down 1% about 1 hour ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Synairgen Plc Description

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.


Sector: Healthcare
Industry: Biotechnology
Keywords: Health Bank Medicine Clinic Disease Diseases Therapy Beta Biology Rtt Respirator Drug Discovery Therapies In Vitro Respiratory Disease Chronic Obstructive Pulmonary Disease Respiratory Diseases Respiratory Therapy Astrazeneca Copd Fibrosis Asthma Chronic Lower Respiratory Diseases

Is SNG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 223.8
52 Week Low 76.5
Average Volume 2,149,647
200-Day Moving Average 157.92
50-Day Moving Average 171.85
20-Day Moving Average 181.95
10-Day Moving Average 182.61
Average True Range 12.64
ADX 18.67
+DI 28.85
-DI 12.66
Chandelier Exit (Long, 3 ATRs) 172.08
Chandelier Exit (Short, 3 ATRs) 192.92
Upper Bollinger Bands 202.80
Lower Bollinger Band 161.10
Percent B (%b) 1.04
BandWidth 22.92
MACD Line 5.20
MACD Signal Line 2.71
MACD Histogram 2.4927
Fundamentals Value
Market Cap 409.02 Million
Num Shares 200 Million
EPS -3.40
Price-to-Earnings (P/E) Ratio -60.18
Price-to-Sales 759.00
Price-to-Book 24.66
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 221.79
Resistance 3 (R3) 221.68 215.84 218.93
Resistance 2 (R2) 215.84 211.46 215.90 217.97
Resistance 1 (R1) 210.22 208.76 207.30 210.33 217.01
Pivot Point 204.38 204.38 202.92 204.44 204.38
Support 1 (S1) 198.76 200.00 195.84 198.87 192.19
Support 2 (S2) 192.92 197.30 192.98 191.23
Support 3 (S3) 187.30 192.92 190.28
Support 4 (S4) 187.41